Methionine sulfoxide reductase A down-regulation in human breast cancer cells results in a more aggressive phenotype

Antonella De Lucaa,b,1 Fabio Sannaa,b,1 Michele Sallese, Carmen Ruggiero, Mauro Grossi, Paolo Sacchettab, Cosmo Rossia, Vincenzo De Laurenzia, Carmine Di Ilio,1, and Bartolo Favaloro*a,b,2

*Unit of Gene Regulation, Fondazione “G. D’Annunzio”, Centro Studi sull’Invecchiamento, 66013 Chieti, Italy; bDepartment of Biomedical Sciences, University of Chieti “G. D’Annunzio” School of Medicine, 66013 Chieti, Italy; and cUnit of Genomic Approaches to Membrane Traffic, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro, Chieti, Italy

Edited* by Herbert Weissbach, Florida Atlantic University, Jupiter, FL, and approved September 20, 2010 (received for review July 14, 2010)

Breast cancer is one of the most frequent of human malignancies, and it is therefore fundamental to identify the underlying molecular mechanisms leading to cancer transformation. Among other causative agents in the development of breast cancers, an important role for reactive oxygen species (ROS) has emerged. However, most studies on the role of ROS in cancer have not reached specific conclusions, and many issues remain controversial. In the present study, we show that methionine sulfoxide reductase A (MsrA), which is known to protect proteins from oxidation and which acts as a ROS scavenger, is down-regulated in a number of breast cancers. Moreover, levels of MsrA correlate with advanced tumor grade. We therefore investigated the functional role of MsrA in breast cancer cells. Our data show that reduction of MsrA levels results in increased cell proliferation and extracellular matrix degradation, and consequently in a more aggressive cellular phenotype, both in vivo and in vitro. We also show that the underlying molecular mechanisms involve increased ROS levels, resulting in reduction of phosphatase and tensin homolog deleted on chromosome ten protein (PTEN), and activation of the phosphoinositide 3-kinase pathway. In addition, MsrA down-regulation results in up-regulation of VEGF, providing additional support for tumor growth in vivo.

matrix degradation | oxidative damage

Cancer cells show increased reactive oxygen species (ROS) generation, which might promote cell proliferation and which, in many cases, might be coupled to redox adaptation promoting cell survival and drug resistance (1). Under persistent intrinsic oxidative stress, many cancer cells become well adapted to such stress and develop an enhanced, endogenous antioxidant capacity, which can make malignant cells resistant to exogenous stress (2–4). In addition, this adaptation can contribute to malignant transformation, metastasis, and resistance to anticancer drugs (5–7).

Animal studies using either gene KO or transgenic overexpression approaches have demonstrated potential roles for antioxidant enzymes, such as superoxide dismutase (SOD), glutathione peroxidases (GPx), and peroxiredoxin as tumor suppressors (8–10). In contrast, studies using primary cancer tissues have revealed increased activities of certain ROS-scavenging enzymes and elevated expression of antioxidant molecules (11–13). Among the several adaptive responses, even under high oxygen conditions, increased aerobic glycolysis (known as the Warburg effect) is commonly seen across a wide spectrum of human cancers (14). Enhanced glycolysis protects cells from oxidative stress and it has been suggested that the Warburg effect reflects a mechanism for escaping the restrictions to cell life span resulting from oxidative stress (15).

The mitochondria and the Nox system of NAPDH oxidases are a major source of ROS production (16, 17). Several reports have demonstrated strong correlations between Nox isoenzyme overexpression, H2O2 generation, and tumorigenicity. Indeed, transfection of Nox1 into a prostate cancer cell line dramatically enhanced tumor growth (18), and Nox1 has been shown to be highly expressed in human colon and prostate cancers (19). H2O2 can alter the redox state of the cell by reacting directly with thiol amino acid residues, i.e., cysteine and/or methionine, within redox-sensitive proteins. The methionine sulfoxide reductase (Msr) system is a multigene family of the constitutively expressed proteins MsrA, MsrB1, MsrB2, MsrB3a, and MsrB3b, which are involved in regeneration of methionine from its oxidized form, Met(O). In addition to its established role in protein repair, the Msr system has been proposed to act as a ROS scavenger (20, 21) and, for this reason, is considered to be an important component of the defense mechanisms against oxidative damage. MsrA is one of the major enzymes involved in reduction of methionine sulfoxide moieties, and it is involved in the regulation of signaling pathways, such as phosphorylation. Calcium/calmodulin-dependent protein kinase II (CaMKII) is a pivotal signaling molecule activated by ROS, and its methionine oxidation is reversed by MsrA (22). MsrA has been localized to several cell organelles, including the mithocondria, nuclei, and endoplasmic reticulum (21, 23), and various studies have shown that MsrA is down-regulated in several human tumors. As an example, leukemia and lymphoma cell lines do not express MsrA mRNA, whereas normal peripheral blood leukocytes do (24). In addition, it has been shown that both MsrA mRNA and protein are decreased in hepatocellular carcinoma (25). Finally we have recently shown significantly lower MsrA expression in breast cancer MCF7 cells, compared with HEK-293 cells (26). Altogether, these reports support a possible role for MsrA in breast cancer carcinogenesis.

Here, we shown that MsrA gene expression is down-regulated in human breast cancers, and that silencing MsrA in a breast cancer cell line results in increased aggressiveness of these cells. This is due at least in part to increased ROS levels, which in turn cause extracellular matrix degradation. Finally, we show that this is linked to alterations of the PI3K pathway. Moreover, MsrA silencing affects VEGF expression, promoting accelerated xenograft growth in vivo.

Results

MsrA Expression Is Down-Regulated in Human Breast Cancer. MsrA down-regulation has been reported in only a few cancer systems (24, 25, 27). To investigate whether this can be considered

1To whom correspondence should be addressed. E-mail: b.favaloro@unich.it.
2This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1010171107/-/DCSupplemental.
a common characteristic of cancer cells, we evaluated MsrA gene expression using a real-time PCR-based tissue array of human breast tumors. Overall, 48 samples were analyzed, seven from normal mammary tissue and the remaining 41 from breast cancer tissue. MsrA expression was down-regulated in the breast cancer samples as compared with the normal tissue. As shown in Fig. 1A, in 34 of 41 breast cancer samples, MsrA expression levels were below the mean value of the MsrA transcript detected in normal tissues. The expression of MsrA mRNA significantly correlated with histological nuclear grade (Nottingham G1/G3). Cancer samples from patients with a tumor classified as G1 or G2 showed higher levels of MsrA expression, as compared with patients with a G3 tumor grade (Fig. 1B).

Knockdown of MsrA Increases H2O2 Levels and Protein Oxidation in MDA-MB231 Breast Cancer Cells. To gain further insight into the specific function of MsrA in cancer, we developed an shRNA interference approach to down-regulate MsrA expression in MDA-MB231 breast cancer cells. As shown in Fig. 2 A and B, MsrA expression was decreased by 90% in silenced MDA-MB231 cells (sh1, sh2, and sh3), as compared with parental and control transfected (c1, c2, and c3) cells. Based on these data, we selected two clones, sh1-MsrA and sh2-MsrA. Both of these clones were used in this study and produced identical results: thus, we present here the data from only the sh1-MsrA clone (shMsrA). Stable transfection of MDA-MB231 cells with an unrelated shRNA (directed against GFP) had no effects on MsrA mRNA levels (Fig. S1).

We then examined whether suppression of MsrA could be compensated for by altered expression of enzymes involved in the “classical” antioxidant defense system. However, there were no differences in the expression levels of SOD, catalase and GPx in shMsrA MDA-MB231 cells (Fig. S2). In addition, MsrB1, MsrB2, MsrB3a, and MsrB3b expression levels were not influenced by MsrA silencing (Fig. S3). These data suggest a direct involvement of MsrA in the control of cellular H2O2 levels in breast cancer cells. MsrA KO mice are more sensitive to oxidative stress and accumulate higher levels of carbonylated proteins (29). Therefore, to investigate whether MsrA silencing leads to nonreversible

MsrA KO mice are more sensitive to oxidative stress and accumulate higher levels of carbonylated proteins (29). Therefore, to investigate whether MsrA silencing leads to nonreversible effects of MsrA silencing, we investigated the possibility that MsrA is a regulator of ROS effects and levels in cancer cells. Indeed, in immunofluorescence studies, we observed that MsrA-deficient cells (shMsrA) had higher ROS levels compared with mock MDA-MB231 cells (Fig. 2C). These data were confirmed by flow cytometry (Fig. S1B). This increase in intracellular oxidants revealed by the ROS-sensitive fluorescent dye dichlorofluorescein diacetate (DCFDA) is most likely due to the production of hydrogen peroxide, to which this probe is selectively sensitive. A general ROS-quenching agent N-acetyl cysteine (NAC) reduced ROS levels induced by the silencing of MsrA (Fig. S1).

In addition to mitochondria, ROS generated through the extramitochondrial NADPH oxidase system are also implicated in mitogenic signaling (28). To identify the source of ROS generation, we evaluated the effects of the Nox inhibitor diphenyliodonium (DPI) and of the mitochondrial complex I inhibitor rotenone on H2O2 levels in shMsrA and mock MDA-MB231 cells. Both DPI and rotenone inhibited ROS generation in MsrA silenced cells. These inhibitors had almost no effect on mock cells (Fig. 2D). Taken together, these data suggest the involvement of the Nox system and the mitochondria in the increased production of ROS observed in cells in which MsrA was down-regulated.

The Msr enzymes might have important roles in ROS scavenging through the “repairing” of oxidized methionine residues (20, 21). Thus, we investigated the possibility that MsrA is a regulator of ROS effects and levels in cancer cells. Indeed, in immuno...
posttranslational modifications, we examined the protein-carbonyl status of the shMsrA MDA-MB231 cells vs. control cells. Our data show that silencing of MsrA results in a significant increase of the cell protein carbonylation status (Fig. 2E).

**MsrA Down-Regulation Increases Cell Invasion.** To determine whether MsrA down-regulation affects cell invasion, we investigated its effects on the degradation of the extracellular matrix (ECM), an event representative of cell invasion ability. In shMsrA MDA-MB231 cells, the ECM degradation area was sixfold greater than in mock-transfected cells (Fig. 3 A and B). Therefore the presence of MsrA appears to protect MDA-MB231 cells from acquiring a more invasive phenotype. In addition, these shMsrA MDA-MB231 cells also showed less organized actin filaments (Fig. 3A), which could again correlate with the acquisition of a more malignant phenotype, as reported previously (30). To investigate whether the increased ECM degradation was dependent on the increase in ROS levels, we performed ECM degradation assays in cells treated with the general ROS-quenching agent NAC and with the NADPH oxidase inhibitor DPI. Both compounds reduced the degradative activity of shMsrA-treated cells by more than sixfold, as compared with vehicle-treated cells (Fig. 3C).

Phosphatase and tensin homolog deleted on chromosome ten protein (PTEN) is considered to be the main negative regulator of the PI3K pathway, and it is frequently inactivated in human cancers; previous studies have indicated that ROS can affect phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P₃) levels in cells by oxidizing PTEN (31, 32). Thus, we asked whether the observed increase in ECM degradation depends on this signaling pathway. Treatment of cells with the PI3K inhibitor LY294002 results in a greater than eightfold decrease of the degradation activity of shMsrA MDA-MB231 cells (Fig. 3C). We next examined PTEN protein levels in shMsrA MDA-MB231 cells and control cells. As shown in Fig. 3D, silencing of MsrA significantly decreases endogenous PTEN protein levels, whereas no effects are seen on PTEN mRNA levels (Fig. 3E), suggesting that MsrA regulates PTEN at the posttranscriptional level.

**Silencing MsrA Enhances 3D Growth of MDA-MB231 Cells.** The silencing the Mrsa gene in “normal” cells, such as melanocytes, has been shown to result in reduced cell viability (33). To investigate the functional effects of the down-regulation of MsrA expression in breast cancer cells, we evaluated cell proliferation both by methyl thiazolyl tetrazolium (MTT) assay and by direct cell counting. The number of shMsrA MDA-MB231 cells was similar to the number of mock MDA-MB231 cells, and a similar result was seen for cell viability using the MTT assay (Fig. 4A), suggesting that MsrA down-regulation does not affect breast cancer cell viability or growth.

Many studies have indicated that basal membranes can serve as barriers to prevent tumor cell entry into adjacent tissues (34, 35). As reported above, the growth of shMsrA MDA-MB231 cells was similar to mock MDA-MB231 cells on plastic surfaces. However, to determine whether growth differences might be observed in a more complex microenvironment, more similar to basal membranes, we evaluated the growth of shMsrA MDA-MB231 cells cultured in Matrigel (BD Biosciences). Under these experimental conditions, shMsrA MDA-MB231 cells produced much larger colonies than control cells (Fig. 4B); moreover, direct cell counting showed higher numbers of cells for shMsrA MDA-MB231 cells than for mock cells (Fig. 4C). Interestingly, DPI treatment significantly reduced the size and numbers of colonies grown on Matrigel (Fig. 4B), although, surprisingly, NAC had no effect on the size of the colonies on Matrigel. In line with these data, it has been recently reported that ROS generation, rather than ROS accumulation, is essential for the aggressive cell phenotype of prostate cancer cells (36). Indeed, in shMsrA MDA-MB231 breast cancer cells, inhibition of ROS generation (DPI) blocked cell growth, whereas the ROS accumulation inhibitor NAC did not (Fig. 4B). The same treatments had no effect on the growth of control cells (Fig. S4). These data suggest that MsrA down-regulation can facilitate the growth of breast cancer cells at tissue boundaries, accelerating the entry of tumor cells into adjacent tissues via a growth-related mechanism that is dependent on Nox generation of H₂O₂.

To determine whether the signaling mechanisms involved in increased cell invasion capacity is also implicated in the enhanced growth of shMsrA MDA-MB231 cells, we performed 3D growth experiments in the presence of the PI3K inhibitor LY294002. LY294002 markedly blocked shMsrA MDA-MB231 colony growth of shMsrA MDA-MB231 cells, we performed 3D growth experiments in the presence of the PI3K inhibitor LY294002. LY294002 markedly blocked shMsrA MDA-MB231 colony growth.
endogenous ROS levels are very important for inducing angiogenic activation of VEGF transcription and expression, suggesting that ovarian cancer cells, ROS hyperproduction was shown to positively regulate VEGF expression. (A) Representative double staining of control (mock) and MsrA-deficient (shMsrA) cells grown on crosslinked-rhodamine-conjugated gelatin (red) overnight and then fixed and labeled with Alexa Fluor 488-phalloidin (green) for F-actin staining. Dark holes on gelatin matrix (black arrows) represent areas of degradation. (B) Quantification of degradation areas in at least 100 cells using LSM510-3.2 software (Zeiss); data are mean of three independent experiments. (C) MsrA-deficient (shMsrA) cells were plated onto crosslinked rhodamine-conjugated gelatin for 24 h in the presence of B894, a broad-spectrum metalloprotease inhibitor, and pretreated with vehicle alone (untreated) or with NAC (10 mM), DPI (10 μM), or LY294002 (10 μM, added during the last 30 min). Following B894 washout, cells were treated overnight with vehicle alone (untreated) or with NAC, DPI or LY294002 at the same concentrations as above. Samples were then fixed and processed for F-actin staining. Degradation area per cell was quantified in at least 100 cells using LSM510-3.2 software (Zeiss); data are mean of three independent experiments. (D) Representative Western blot of PTEN protein levels. β-Actin was used as loading control. Data are mean ± SD (n = 3). *P < 0.02. (Right) Quantification using densitometric analysis. (E) Representative RT-PCR analysis of PTEN transcript levels. Data are mean ± SD (n = 3). (Right) Quantification using PCR densitometric analysis.

growth on Matrigel (Fig. 4B and Fig. S4), thus suggesting that PI3K-dependent activation is critically involved in promoting growth of shMsrA MDA-MB231 cells in this 3D culture system.

MsrA Silencing Induces VEGF Production in MDA-MB231 Cells and Promotes Growth of Tumor Xenografts in Nude Mice. In human ovarian cancer cells, ROS hyperproduction was shown to positively regulate VEGF transcription and expression, suggesting that endogenous ROS levels are very important for inducing angiogenesis and consequently tumor development (37). We therefore investigated whether modulation of MsrA affects VEGF expression. Our results show that down-regulation of MsrA results in increased VEGF protein (Fig. S4A) and mRNA levels (Fig. 5B), and thus potentially also angiogenesis and tumor growth in vivo.

Finally, to determine whether MsrA silencing has similar effects in vivo, we used a xenograft tumor model in athymic mice. Subcutaneous injections in CD-1 nude mice were administered with mock-transfected and shMsrA MDA-MB231 cells, to evaluate the formation of solid tumor xenografts. Indeed, the mice had to be killed 48 d after the injections due to the rapid growth of the shMsrA MDA-MB231 cell tumors, which were dramatically larger than those formed by mock-transfected cells (Fig. 5C and E). The effective silencing of MsrA gene was verified in tumors recovered from mice injected with shMsrA MDA-MB231 cells (Fig. 5D). These data demonstrate that down-regulation of MsrA dramatically enhances the growth of tumors in vivo.

Discussion

In the present study, we provide evidence supporting the idea that loss of MsrA is a favorable condition for tumor cell growth. Although it has been reported that the knockdown of MsrA in melanocytes results in reduced cell viability (33), we did not detect growth variations between MsrA-silenced and control breast cancer cells. It is important to specify that this finding is only true when cells were grown as 2D monolayers. Culturing cells in 3D provides another dimension for external mechanical input and for cell adhesion, which affects integrin ligation, cell contraction, and associated intracellular signaling (38). In agreement with this, MsrA-silenced breast cancer cells showed dramatic increases in growth under 3D conditions. Normal and cancer cells have different oxidative metabolism systems. Cancer cells have a higher rate of glycolysis than normal cells (i.e., the Warburg effect). This leads to hyperactivation of the pentose phosphate pathway, generating high levels of NADPH (39). NADPH is crucial for glutathione reductase activity as well as for other enzymes involved in oxidative defense mechanisms. On the other hand, NADPH is a substrate for ROS generation by the Nox system. These two different pathways need to be carefully balanced in cancers because ROS hyperproduction will kill the cancer cells (40), whereas a modest ROS increase represents a favorable condition for tumor growth. Indeed, here, we have demonstrated that MsrA silencing promotes a modest increase in ROS levels (doubled), thus favoring the Nox-dependent 3D growth of MDA-MB231 cells.
One of the most important causes of poor prognosis in cancer patients is tumor cell invasion of distal organs, with the formation of metastases. The complex process of metastasization requires the integration of several events, including the dissociation of cells from the primary tumor in association with local remodeling/degradation of the ECM (41). Invasive cancer cells cultured on physiological substrates can degrade the underlying matrix through specialized membrane protrusions that are rich in actin filaments and are known as invadopodia. These invadopodia are thought to be necessary for carcinoma cell invasion, through the local remodeling of the ECM structures in the path of invading cells (42, 43). Interestingly, it has recently been shown that ROS generated by the Nox system are necessary for controlling tumor growth, we investigated tumor growth in nude mice. Tumours derived from shMsrA MDA-MB231 cells were larger than those derived from control cells, confirming in vivo the increased growth detected under our 3D in vitro conditions. Thus, our data suggest that the MsrA down-regulation observed in primary tumors is essential for acceleration of tumor growth (24, 25).

In conclusion, we show that MsrA is down-regulated in human breast cancers and that its down-regulation results in a clear growth advantage for these cells both in vitro and in vivo, with a more aggressive cellular phenotype seen. Moreover, we show that MsrA regulates its effects through a ROS-dependent activation of the PI3K pathway, as well as increased production of VEGF. Interestingly, we demonstrate that lower MsrA levels correlate with higher tumor grade (G1/G2 vs. G3). These findings suggest that MsrA has antitumor effects, thus suggesting a promising strategy for the treatment of breast cancer.

Materials and Methods

Quantitative Real-Time PCR (Disease Tissue qPCR Arrays). To evaluate MsrA expression levels, we used a real-time PCR-based tissueScan Breast Tissue qPCR Array, containing seven normal cDNAs and 41 human breast cancer cDNAs, normalized using the house-keeping gene β-actin (BCRT101, OriGene Technologies). Real-time PCR was performed using a TaqMan Universal PCR Master Mix (Applied Biosystems), according to the manufacturer’s instructions. The human-specific probe set for MsrA was obtained from ABI (Hs00737166-m1). VEGF real-time PCR data are reported in SI Materials and Methods.

Silencing of MsrA in MDA-MB231 Cells. MDA-MB231 human breast cancer cells (obtained from ATCC) were maintained in a humidified atmosphere containing 5% CO2 at 37 °C, in DMEM containing high glucose (4.5 g/L, or 25 mM) supplemented with 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin.

Cells were transfected using Lipofectamine 2000 (Invitrogen) with the pRS vector (Origene # TR20003), pRS-shGFP (Origene # TR30003, encoding non-effective 29-mer shGFP cassette as a negative control), or with specific MsrA-directed 29-mer shRNA oligos (Origene; MsrA-shRNA; Table S1), according to the manufacturer’s instructions. Stable clone selection procedures are reported in SI Materials and Methods.

Western Blotting. Western blotting details and antibodies used in this study are reported in SI Materials and Methods.

Determination of Cellular ROS. The ROS-fluorescent probe DCFDA (2,7-dichlorofluorescin diacetate, 287810; Calbiochem) was used to detect endogenous ROS levels. The cells were plated in 24-well plates and incubated overnight at 37 °C. The cells were then washed twice with PBS and incubated with 10 μM DCFDA in PBS for 30 min at 37 °C in the dark. Imaging was performed using a caliper in live mice. Data are mean ± SD (n = 3). *P < 0.01. (C) Representative tumors recovered from athymic nude mice injected s.c. into right and left flanks with either mock or shMsrA MDA-MB231 cells (8 × 10^7) (n = 10 per treatment group). (D) MsrA transcript levels were determined by RT-PCR in tumors recovered from mice injected with either mock or shMsrA MDA-MB231 cells. (E) Tumor growth over time (as days after implantation) evaluated using a caliper in live mice. Data are mean ± SEM. *P < 0.05.
formed using an Inverted Nikon Eclipse TE2000-U wide-field fluorescence microscope. Changes in ROS production in stably transfected cells were measured using DCFDA. Cells (2 × 10^6) were cultured in 96-well plates at 37 °C overnight and then treated with 10 μM DPI or 5 μM rotenone for 1 h. The cells were incubated with 10 μM DCFDA for 30 min at 37 °C. ROS levels were measured using a SPECTRAmax GEMINI spectrofluorometer (Molecular Devices, excitation wavelength, 490 nm; emission wavelength, 535 nm).

**Protein Carboxylation Detection.** Protein oxidation was revealed using OxyBlot Protein Oxidation Detection kits (Chemicon International). Briefly, 2,4-dinitrophenylhydrazine was added to whole-cell extracts to derivatize the carbonyl groups in the protein side chains to 2,4-dinitrophenyldihydrazine (DNP), which was then revealed by Western blotting with anti-DNP antibodies.

**ECM-Degradation Assay.** Details of the fluorophore-conjugated gelatin preparation and the quantification of ECM degradation are reported in SI Materials and Methods.

2D Cell-Proliferation Assay and Cell Growth. The proliferation of cells was measured using CellTiter 96 AQueous One (Promega). Details are provided in SI Materials and Methods.

**2D Cell-Proliferation Assay and Cell Growth.** The proliferation of cells was measured using CellTiter 96 AQueous One (Promega). Details are provided in SI Materials and Methods.

**3D Cell Culture.** To study cell behavior in three dimensions, the cells were embedded in Growth Factor Reduced Matrigel (BD Biosciences), according to the manufacturer’s recommendations. Details are given in SI Materials and Methods.

**Nude Mice Xenograft Analysis.** All procedures involving nude mice were conducted in compliance with institutional guidelines and with national (D.L. No. 116, G.U., Suppl. 40, February 18, 1992; Circolare No. 8, G.U., July 1994) and international (U.K.C.CCR Guidelines for the Welfare of Animals in Experimental Neoplasia; EEC Council Directive 86/609, OJ L 358, 1, December 12, 1987) laws and policies. 5×10^6 cells resuspended in 200 μL PBS were injected s.c. into the flanks of 6- to 8-wk-old CD-1 athymic nude mice (Charles River Laboratories). Tumor growth was monitored using calipers. Tumor volume was determined using the following equation: volume = width^3 x length/2. The tumors were recovered and photographed following necropsy.

**ACKNOWLEDGMENTS.** We thank Dr. Monica Franciosi for help with the statistical analysis, and Professor Mauro Plantelli for helpful suggestions. This study was supported in part by grants from Fondi Ricerca Scientifica di Ateneo (ex 60%) (to B.F. and C.D.I.), Associazione Italiana per la Ricerca sul Cancro, and Ministero dell’Istruzione Università e Ricerca (to V.D.L.).